Welcome to our dedicated page for ImageneBio SEC filings (Ticker: IMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ImageneBio, Inc. filings document a Nasdaq-listed biotechnology issuer focused on IMG-007, its anti-OX40 receptor antagonist program for autoimmune and inflammatory diseases. Its 8-K reports disclose operating results, program updates, Regulation FD materials, private-placement and capital-structure matters, and officer or director changes.
Proxy materials cover annual meeting proposals, director elections, auditor ratification, equity incentive plan amendments, and executive compensation governance. The filing record also identifies the company’s common stock on The Nasdaq Capital Market and records formal disclosures tied to its completed reverse-merger corporate history.
Imagenebio, Inc. received an amended Schedule 13G showing that Deep Track Capital, Deep Track Biotechnology Master Fund, Ltd., and David Kroin now report zero beneficial ownership of the company’s common stock. Each reporting person lists 0 shares with 0% of the class and no voting or dispositive power. The filing confirms they own 5 percent or less of Imagenebio’s common stock. The ownership calculations use 11,181,672 shares outstanding as of November 3, 2025, as disclosed in Imagenebio’s prior quarterly report.
ImageneBio, Inc. received a Schedule 13G filing showing that Blue Owl Capital Holdings LP beneficially owns 823,785 shares of ImageneBio common stock. This represents 7.37% of the company’s outstanding common shares, based on 11,181,672 shares reported as outstanding as of November 3, 2025.
Blue Owl reports sole voting and dispositive power over all 823,785 shares and no shared power. The firm certifies that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of ImageneBio.
ImageneBio, Inc. has filed a prospectus supplement covering the proposed offer and resale from time to time by selling stockholders of 2,508,337 shares of common stock. The supplement incorporates information from a recent current report that notes Chief Medical Officer Yufang Lu, M.D., Ph.D. has notified the company of her resignation, effective December 31, 2025. The company states that her resignation is not due to any disagreement related to operations, policies or practices. ImageneBio is conducting a search for her replacement, and Dr. Lu is expected to provide transition advisory services after her resignation date. The company’s common stock trades on the Nasdaq Capital Market under the symbol IMA, and last traded at $6.24 per share on December 17, 2025.
Imagenebio, Inc. reported that its Chief Medical Officer, Yufang Lu, M.D., Ph.D., has given notice of her resignation effective December 31, 2025. The company states that Dr. Lu’s decision is not due to any disagreement regarding its operations, policies, or practices, which suggests the change is not driven by internal conflict.
Imagenebio is beginning a search for a new Chief Medical Officer, an important role overseeing its medical and clinical programs. Dr. Lu is expected to provide transition advisory services after her resignation date, helping to maintain continuity in the company’s clinical and medical activities while leadership responsibilities are handed over to her eventual successor.
IMAGENEBIO, INC. (IMA) filed a current report to announce that it has updated its corporate presentation for use in meetings with investors, analysts and other interested parties. The updated presentation, dated November 19, 2025, is being made available on the company’s website and is also included as Exhibit 99.1 to this report.
The company notes that the information in this investor presentation and in this report under Item 7.01 is being furnished rather than filed under securities laws, which means it is not automatically incorporated into other securities filings unless specifically referenced there.
ImageneBio, Inc. (IMA) filed a Form S-8 to register new shares for employee and equity plans. The filing covers 1,118,167 shares of common stock issuable under the ImageneBio, Inc. 2025 Equity Incentive Plan, 111,816 shares under the 2025 Employee Stock Purchase Plan, 589,585 shares under the 2025 Equity Inducement Plan, and 455,938 shares under the Inmagene Biopharmaceuticals 2019 Stock Incentive Plan.
The company notes it completed a merger on July 25, 2025, after which it assumed Legacy Inmagene’s 2019 Stock Incentive Plan and converted outstanding options into options for ImageneBio common stock. The filing also describes standard Delaware-law indemnification for directors and officers, the company’s charter and bylaw protections, and related insurance coverage. This registration facilitates future issuances to employees, directors, and other service providers pursuant to the specified plans.
ImageneBio, Inc. filed a prospectus supplement covering the proposed offer and resale, from time to time, by selling stockholders of 2,508,337 shares of common stock.
The supplement updates the base prospectus by attaching the company’s Quarterly Report on Form 10-Q filed on November 12, 2025. ImageneBio’s common stock trades on the Nasdaq Capital Market under the ticker IMA; the last reported sales price was $8.61 per share on November 11, 2025. The filing reiterates that investing in the securities involves a high degree of risk, directing readers to the Risk Factors in the prospectus.
ImageneBio, Inc. (IMA) filed its Q3 2025 10‑Q and reported a transformative quarter driven by a reverse recapitalization with Ikena Oncology and a concurrent PIPE financing. The company ended September 30, 2025 with cash, cash equivalents and marketable securities of $142.6 million, positioning it to fund operations for at least the next 12 months.
For the quarter, ImageneBio recorded a net loss of $24.8 million, reflecting research and development expense of $15.6 million and general and administrative expense of $11.0 million as it advances its lead program, IMG‑007, a non‑depleting anti‑OX40 monoclonal antibody. For the nine months ended September 30, 2025, net loss totaled $38.4 million.
The July 25, 2025 reverse recapitalization brought in Ikena’s net assets (including $54.6 million of cash and $40.1 million of marketable securities) and the company raised additional capital via a 2,508,339‑share PIPE for approximately $75.0 million gross. A related $22.5 million pre‑merger term loan was forgiven at closing. ImageneBio also completed a Non‑OX40 divestiture, recording a related $7.5 million promissory note receivable and an offsetting CVR liability of $7.5 million. Shares outstanding were 11,181,672 as of November 3, 2025.
ImageneBio, Inc. filed a current report to note that it released its financial results for the quarter ended September 30, 2025. The company announced these quarterly results through a press release dated November 12, 2025, which is included as an exhibit to the report.
The press release is furnished as Exhibit 99.1 and is not deemed filed for liability purposes under the federal securities laws. ImageneBio’s common stock trades on The Nasdaq Capital Market under the symbol IMA.
ImageneBio, Inc. (IMA) reported an insider ownership update. A director filed a Form 3 initial statement of beneficial ownership effective 11/01/2025, indicating no securities are beneficially owned. The filing was made by one reporting person, and includes an Exhibit 24 Power of Attorney authorizing the attorney-in-fact to sign on the reporting person’s behalf.
This is a routine disclosure establishing the insider’s baseline ownership at the time they became subject to reporting.